The U.S. Food and Drug Administration has approved Jakafi (ruxolitinb), the first drug approved to treat patients with the bone marrow disease myelofibrosis. Read more.
The U.S. Food and Drug Administration has approved Jakafi (ruxolitinb), the first drug approved to treat patients with the bone marrow disease myelofibrosis. Read more.